Biohit Oyj Stock Exchange Release November 18, 2013 at 11:45 a.m. local time (EET)
Biohit Oyj acquires the rights to the UFT300 test, which is a rapid test for the diagnosis of Helicobacter pylori infection. Along with the agreement, the Italian developer, Advanced Biomedical Systems s.r.l. (ABS) gives Biohit the patent and distribution rights for the test. The purchase price is EUR 350,000 and the new H. pylori quick test will be incorporated into Biohit’s product range during the fourth quarter, 2013.
UFT300 is the only test available on the market which permits the reading of the result as well as confirmation within 5 minutes from the sample insertion; UFT300 combines the superior performance characteristics (sensitivity 94,5%, specificity 100%, accuracy 97,5%) with the maximum speed if compared with all the competitors' tests commercially available worldwide (1). After a transition period, the rights to the earlier version of the test (UFT200) will also be transferred to Biohit.
CEO Semi Korpela, Biohit Oyj: "This is bad news for helicobacter. Our test is superior.”
Source (1): Vaira D et al 2010 Accuracy of a new ultrafast rapid urease test to diagnose Helicobacter pylori infection in 1000 consecutive dyspeptic patients
Attachment: UFT300 Urea Ultra-Fast test for diagnosing H. pylori infection
Additional information:
CEO Semi Korpela, Biohit Oyj
Tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit's mission is "Innovating for Health". The purpose of the company is to take social responsibility and produce innovation, new technologies and analysis systems for use in medicine, research institutions and industry, helping to promote research and diagnostics and to improve the quality of life of people by means of preventing disease, human suffering and financial loss. We are committed to social responsibility and it is our duty to spread knowledge about the Group I human carcinogen, acetaldehyde, and innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki, Finland and its subsidiaries are located in China, Italy and the United Kingdom. Since 1999, Biohit's Series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector. www.biohithealthcare.com
